Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases.

Abstract

BACKGROUND C-C chemokine receptor 2 (CCR2) antagonists belong to a group of chemokine blockers, which represent a new strategy for inflammatory diseases treatment by interfering with the complex system of chemokines and their receptors. A number of CCR2 antagonists are being developed for treatment of autoimmune diseases by different pharmaceutical and biotechnological companies. OBJECTIVE In this article the dark and the bright side of therapeutic CCR2 antagonism is discussed, with a view to its potential efficacy in various autoimmune diseases, in which clinical trials are already in progress, such as multiple sclerosis and rheumatoid arthritis. We describe different modes of possible interactions with CCR2-chemokine CC motif ligand 2 (CCL2) axis, usefulness of experimental animal models, continuing clinical trials and future perspectives of CCR2 antagonists. METHODS Until now only a few peer-reviewed articles providing data on the progress of preclinical and clinical trials with CCR2 antagonists have been published; therefore, we also present data based on preliminary reports, obtained from a number of press releases, conference communications and from the PharmaProjects database. RESULTS/CONCLUSION Although there is growing evidence for a great therapeutic potential of CCR2 blockade in autoimmune diseases, especially well documented in experimental animal models, so far clinical trials with CCR2 antagonists in humans have been moderately encouraging or even disappointing, indicating a need to further elucidate the complex system of chemokine interactions.

DOI: 10.1517/13543784.17.9.1267
020406080200920102011201220132014201520162017
Citations per Year

65 Citations

Semantic Scholar estimates that this publication has 65 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Kalinowska2008InvestigationalCC, title={Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases.}, author={Alicja Kalinowska and Jacek Losy}, journal={Expert opinion on investigational drugs}, year={2008}, volume={17 9}, pages={1267-79} }